Phase 3 Alzheimer’s Disease Clinical Trial

Now Open in Savannah, GA

Alzheimer’s disease is characterized by a loss of cognitive abilities. In early stages, memory loss is mild, but symptoms worsen over time and late stage Alzheimer’s disease can cause individuals to lose the ability to carry on a conversation and respond to their environment.

Meridian is conducting a Phase 3 clinical trial for an investigational antibody intended to target and remove deposited amyloid plaque.

Eligible participants…

  • Must be age 60 to 85
  • Must have experienced gradual and progressive change in memory function for 2 to 6 months
  • May receive compensation for time and travel
  • Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

You can also talk to a Meridian enrollment specialist about this study by calling (912) 354-7676.

Study Location

Meridian Clinical Research
6602 Waters Avenue, Building C
Savannah, GA 31406

Submit your information

Expect Excellence icon - supporting research since 1999

Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services.

Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.